Drug General Information
Drug ID
D09BOH
Former ID
DIB006454
Drug Name
Verubulin
Synonyms
Azixa; Verubulin hydrochloride; EP-128495; MPC-6827; Apoptosis inducer (cancer), Myriad; Caspase inducer (cancer), Myriad; Cell cycle arrest inducer (cancer), Myriad; Tubulin inhibitor (cancer), Myriad
Drug Type
Small molecular drug
Indication Brain metastases [ICD-11: 2D50; ICD-10: C79.3; ICD-9: 198.3] Phase 2 [1]
Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] Phase 2 [2]
Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] Phase 2 [1], [3]
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] Phase 2 [4]
Company
Maxim Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL

Formula
C17H17N3O
Canonical SMILES
N(c1nc(nc2c1cccc2)C)(C)c1ccc(cc1)OC
CAS Number
CAS 827031-83-4
PubChem Compound ID
Target and Pathway
Target(s) Tubulin beta (TUBB) Target Info Modulator [5]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
Panther Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
REF 1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 4 ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health.
REF 5 Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.